$10.47
-0.06 (-0.57%)
Affymax, Inc. (NASDAQ:AFFY)
CAPS Rating:
The Company is a biopharmaceutical company developing novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions.
RSS Headlines
Fool UK